目次

esearch Methodology

2. Global Leukemia Antibody Market Overview
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity

3. Global Leukemia Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Patient Segment

4. Leukemia Antibody Drug Conjugates Insight
4.1 Overview
4.2 Drugs Availability, Patent, Price and Dosage Analysis

5. Leukemia Monoclonal Antibody Insight
5.1 Overview
5.2 Drugs Availability, Patent, Price and Dosage Analysis

6. Leukemia Bispecific Antibody Insight
6.1 Overview
6.2 Drugs Availability, Patent, Price and Dosage Analysis

7. Global Leukemia Antibodies - Global and Regional Sales Analysis
7.1 Besponsa
7.2 Rituxan
7.3 Gazyva
7.4 Blincyto

8. Global Leukaemia Antibodies Clinical Pipeline By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
8.7 Preregistration
8.8 Registered

9. Marketed Leukaemia Antibodies Clinical, Patent and Orphan Designation Insight

10. Competitive Landscape
10.1 Amgen
10.2 Amphivena Therapeutics
10.3 AstraZeneca
10.4 Eli Lilly
10.5 GlaxoSmithKline
10.6 Innovent
10.7 Janssen Pharmaceuticals
10.8 Jasper Therapeutics
10.9 Pfizer
10.10 Roche

List of Figures & Tables
Figure 2-1: Global - Leukemia Incidences and Deaths, 2020 and 2030
Figure 2-2: Global - Leukemia Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
Figure 2-3: Global - Leukemia Antibodies Therapeutics Market Size by Type (US$ Million), 2021
Figure 2-4: Global - Leukemia Antibodies Therapeutics Market Size by Type (%), 2021
Figure 2-5: Global - Leukemia Antibodies Therapeutics Market Size by Region (US$ Billion), 2021
Figure 2-6: Global - Leukemia Antibodies Therapeutics Market Size by Region (%), 2021
Figure 2-7: Global - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-8: US - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-9: Europe - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-10: China - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-11: Japan - Leukemia Antibody Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 3-1: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-2: Global - Leukemia Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-3: Global - Leukemia Antibodies in Clinical Trials by Phase, 2022 till 2028
Figure 3-4: Global - Leukemia Antibodies in Clinical Trials by Patient Segment, 2022 till 2028
Figure 4-1: Mylotarg - FDA Approval, Withdrawal and Re-Approval Year
Figure 4-2: Mylotarg - Approval Year by Region
Figure 4-3: UK - Cost of Supply of Mylotarg 5mg Intravenous Powder (GBP/US$), May’2022
Figure 4-4: Mylotarg - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 4-5: Mylotarg - Number of Induction Cycle and Consolidation Cycle Required for Treatment of Newly Diagnosed De Novo CD33-positive AML
Figure 4-6: Mylotarg - Cost of Induction Cycle, Consolidation Cycles and Full Treatment Cost of Newly Diagnosed De Novo CD33-positive AML (US$), May’2022
Figure 4-7: Mylotarg - Recommended Number of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 Positive AML
Figure 4-8: Mylotarg - Length of Induction and Continuation Cycle for Treatment of Newly Diagnosed CD-33 positive AML (Days)
Figure 4-9: Mylotarg - Recommended Dose of Initial Dose and Continuation Dose for Treatment of Newly Diagnosed CD-33 positive AML (mg/m2)
Figure 4-10: Mylotarg - Cost of Induction Phase and Continuation Phase and Full Treatment Cost of CD-33 positive AML (US$), May’2022
Figure 4-11: Mylotarg - Cost of Single Dose and Full Treatment Cost of Relapsed and Refractory CD33 Positive AML, May’2022
Figure 4-12: Besponsa - Approval Year by Region
Figure 4-13: UK - Cost of Supply of Besponsa 0.9mg Intravenous Powder (GBP/US$), May’2022
Figure 4-14: Besponsa - Cost of Supply of Vial for Injection by Region (US$), May’2022
Figure 4-15: Besponsa - Duration of Initial Treatment Cycle and Subsequent Cycles (Days)
Figure 4-16: Besponsa - Recommended Dose for 1st, 8th and 15th Day of Initial Treatment Cycle (mg/m2)
Figure 4-17: Besponsa - Cost of Single Unit and Full Cost of Initial Treatment Cycle (US$), May’2022
Figure 4-18: Besponsa - Duration of Treatment of ALL - After and Without HSCT (Weeks)
Figure 4-19: Lumoxiti - Year of Orphan Designation, FDA Approval and Patent Expiration
Figure 4-20: Lumoxiti - Duration of Single Treatment Cycle and Full Treatment (Weeks)
Figure 4-21: Lumoxitin - Cost of Single Dose, Single Treatment Cycle and Full Treatment of Hairy Cell Leukemia (US$), May’2022
Figure 5-1: Rituxan - FDA Approval Year by Indication
Figure 5-2: MabThera - Approval Year by Region
Figure 5-3: US- Price for a Supply of 10 ml and Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 5-4: US - Price for a Supply of 50 ml and Price Per ml of Rituxan Solution for Injection (US$), May’2022
Figure 5-5: US - Price for a Supply of 100 ml and Price Per ml of Solution Rituxan for Injection (US$), May’2022
Figure 5-6: UK - Price for a Supply of 10 ml and Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 5-7: UK - Price for a Supply of 50 ml and Price Per ml of Rituxan Solution for Injection (GBP/US$), May’2022
Figure 5-8: Rituxan - Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-9: Truxima - Price for a Supply of 10 ml and Price Per ml of Solution for Injection (US$), May’2022
Figure 5-10: Truxima - Price for a Supply of 50 ml and Price Per ml of Solution for Injection (US$), May’2022
Figure 5-11: UK - Cost of 50ml Truxima 500mg/50ml Solution and Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-12: UK - Cost of 2 Vials of Truxima 100mg/10ml Solution and Per Unit Cost of Vial (GBP/US$), May’2022
Figure 5-13: Truxima - Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-14: Riabni - Cost of Supply of 10ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-15: Riabni - Cost of Supply of 50ml and Per Unit Price of 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-16: Riabni - Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-17: Ruxience - Approval Year by Region
Figure 5-18: US - Cost of Supply of 10ml and Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 5-19: US - Cost of Supply of 50ml and Per Unit Price of Ruxience 10mg/ml Intravenous Solution (US$), May2022
Figure 5-20: UK - Cost of 50ml Ruxience 500mg/50ml Solution and Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-21: UK - Cost of 10ml Ruxience 100mg/10ml Solution and Per Unit Cost of Solution (GBP/US$), May’2022
Figure 5-22: Riabni - Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), May’2022
Figure 5-23: Rituxan Hycela - Price for 11.7 ml Supply and Price Per ml of 23,400 units-1,400mg/11.7 ml Subcutaneous Solution (US$), May’2022
Figure 5-24: Rituxan Hycela - Price for 13.4 ml Supply and Price Per ml of 26,800 units-1,600 mg/13.4ml Subcutaneous Solution (US$), May’2022
Figure 5-25: Rituxan Hycela - Duration of CLL Treatment (Weeks)
Figure 5-26: Rituxan Hycela - Cost of Single Treatment Cycle and Full Treatment of CLL (US$), May’2022
Figure 5-27: Gazyva - Approval Year by Cancer Type
Figure 5-28: Gazyva - Price for 40ml Supply and Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-29: Gazyva - Recommended Dosing Schedule for Initial Treatment Cycle of CLL (mg)
Figure 5-30: Gazyva - Duration of Single Treatment Cycle and Full Treatment of CLL (Week)
Figure 5-31: Gazyva - Cost of Initial and Subsequent Treatment Cycle and Full Treatment Cost of CLL (US$), February’2022
Figure 5-32: Arzerra - Price for a Supply of 15 ml, 5 ml and Price per ml of Intravenous Solution (US$), May’2022
Figure 5-33: Arzerra - Price for a Supply of 50 ml and Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-34: Arzerra - Initial and Maintenance Dose for Previously Untreated CLL (mg)
Figure 5-35: Arzerra - Minimum and Maximum Treatment Duration for Previously Untreated CLL (Weeks)
Figure 5-36: Arzerra - Minimum and Maximum Treatment Cost for Previously Untreated CLL (US$), May’2022
Figure 5-37: Arzerra - Initial and Maintenance Dose for Relapsed CLL (mg)
Figure 5-38: Arzerra - Minimum and Maximum Treatment Cost for Relapsed CLL (US$), May’2022
Figure 5-39: Arzerra - Initial and Maintenance Dose for Refractory CLL (mg)
Figure 5-40: Arzerra - Treatment Duration for Refractory CLL (Weeks)
Figure 5-41: Arzerra - Minimum and Maximum Treatment Cost for Refractory CLL (US$), May’2022
Figure 6-1: Blincyto - Number of Induction and Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL
Figure 6-2: Blincyto - Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)
Figure 6-3: Blincyto - Cost of Single Cycle and Full Treatment Cost of MRD+ B-cell precursor ALL (US$), May’2022
Figure 6-4: Blincyto - Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 6-6: Blincyto - Cost of 1st and 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), February’2022
Figure 7-1: Besponsa - Quarter 1 Sales by Region (US$ Million), 2022
Figure 7-2: Besponsa - Quarter 1 Sales by Region (%), 2022
Figure 7-3: Global - Besponsa Annual Sales (US$ Million), 2020 and 2021
Figure 7-4: Global - Besponsa Quarterly Sales (US$ Million), 2020 and 2021
Figure 7-5: US - Besponsa Quarterly Sales (US$ Million), 2020 and 2021
Figure 7-6: Europe - Besponsa Quarterly Sales (US$ Million), 2020 and 2021
Figure 7-7: ROW - Besponsa Quarterly Sales (US$ Million), 2020 and 2021
Figure 7-8: Besponsa - Annual Sales by Region (US$ Million), 2020 and 2021
Figure 7-9: Besponsa - Quarterly Sales by Region (%), 2020
Figure 7-10: Besponsa - Quarterly Sales by Region (%), 2021
Figure 7-11: Rituxan - Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 7-12: Global - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-13: US - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-14: Europe - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-15: Japan - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-16: ROW - Rituxan Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-17: Rituxan - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 7-18: Rituxan - Annual Sales Value by Region (%), 2021
Figure 7-19: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021
Figure 7-20: Global - Rituxan Quarterly Sales Value (US$ Million), 2020
Figure 7-21: Gazyva - Quarter -1 Value by Region (US$/CHF Million), 2022
Figure 7-22: Global - Gazyva Annual Sales Value (US$/CHF Million), 2018 - 2021
Figure 7-23: US - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-24: Europe - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-25: Japan - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-26: ROW - Gazyva Annual Sales Value (US$/CHF Million), 2019 - 2021
Figure 7-27: Gazyva - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 7-28: Gazyva - Annual Sales Value by Region (%), 2021
Figure 7-29: US - Gazyva Quarterly Sales Value (US$ Billion), 2021
Figure 7-30: US - Gazyva Quarterly Sales Value (US$/CHF Million), 2020
Figure 7-31: Blincyto - Quarter 1 Sales by Region (US$ Million), 2022
Figure 7-32: Blincyto - Quarter 1 Sales by Region (%), 2022
Figure 7-33: Blincyto - Sales Value (US$ Million), 2018 - 2021
Figure 7-34: US - Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 7-35: ROW - Blincyto Sales Value (US$ Million), 2018 - 2021
Figure 7-36: Global - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-37: US - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-38: ROW - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 7-39: Blincyto - Annual Sales Value by Region (US$ Million), 2021
Figure 7-40: Blincyto - Annual Sales Value by Region (%), 2021